Using the SPECTROstar Nano for various absorbance experiments

May 31, 2012

Amyloid precursor protein (APP) and beta-amyloid (Aβ) are two proteins known to be involved in neurogenetic disorders, such as Alzheimer's disease, Fragile X syndrome and Down's syndrome.

Image of Dr EJ Dell
Dr EJ Dell
PhD, Sales Manager Northwest
BMG LABTECH USA

Using the SPECTROstar Nano, this laboratory proposed to investigate the genetic and environmental factors affecting these proteins and thus these diseases. The goals set out in this proposal include: defining the molecular and cellular pathways that regulate the synthesis and processing of APP and Aβ in normal and disease-state cells; testing pharmacological interventions (mGluR5 inhibitors and passive immunotherapy) in attenuating APP and Aβ expression and disease phenotypes; and identifying dietary factors (phytoestrogens) that modulate APP and Aβ levels and disease phenotypes in mouse models of neurogenetic disorders.

 

The experiments proposed for the SPETROstar Nano include: routine quantification of DNA and RNA; assessment of protein concentration by BCA assays; and ELISA analyses by both alkaline phosphatase and HRP detection and bacterial growth. In addition, new kinetic assays for the measurement of β-secretase (BACE-1), isomerase and acetylation activities were proposed to be developed using the full-spectrum, shaking, and incubation features of the SPECTROstar Nano.

 

go to top